Liquidia Corporation Stock Price, News & Analysis

Liquidia (NASDAQ: LQDA) will present seven posters on their investigational products, YUTREPIA™ (treprostinil) inhalation powder and L606 (liposomal treprostinil) inhalation suspension, at the 7th World Symposia of Pulmonary Hypertension (WSPH) in Barcelona, Spain, from June 29 to July 1, 2024.

The presentations will include two live poster sessions and five encore presentations, focusing on the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).

Key studies include efficacy analyses, HRCT chest scans, and safety and tolerability assessments. A global, pivotal placebo-controlled efficacy trial for L606 in PH-ILD is planned for later this year.

On May 31, the U.S. District Court for the District of Delaware denied United Therapeutics' motion to block the launch of Liquidia's YUTREPIA for treating pulmonary hypertension associated with interstitial lung disease (PH-ILD). This ruling enables the FDA to finalize its decision on YUTREPIA's amended New Drug Application (NDA) for both PAH and PH-ILD. Liquidia's CEO, Dr. Roger Jeffs, expressed satisfaction with the court's decision, which highlights UTHR's inability to show substantial merit in their obviousness challenge and lack of public interest in an injunction. The ongoing lawsuit, initiated by UTHR in September 2023, cites patent infringement claims, with a trial slated for June 2025. Previous legal bodies have ruled that YUTREPIA does not infringe UTHR's patents, including the Patent Trial and Appeal Board and the U.S. Court of Appeals, which found the '793 Patent claims unpatentable. UTHR intends to appeal these decisions to higher courts.

Liquidia (NASDAQ: LQDA) announced that Michael Kaseta, Chief Operating Officer and Chief Financial Officer, will update the company's business at the 2024 Jefferies Global Healthcare Conference. The presentation will take place on June 5, 2024, at 9:00 a.m. ET in New York City. A webcast of the event will be available on Liquidia's website, with an archived version accessible for at least 30 days post-event.

Liquidia (NASDAQ: LQDA) announced its Q1 2024 financial results and provided a corporate update. The company highlighted its ongoing efforts to secure FDA approval for YUTREPIA, aimed at treating pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Legal barriers for FDA approval were removed, and the company is progressing with the ASCENT study of YUTREPIA.

On the financial front, Liquidia reported a revenue of $3.0 million, a decrease from $4.5 million in Q1 2023. Expenses surged, with R&D rising by 91% to $10.1 million and G&A expenses ballooning by 160% to $20.2 million. Net loss for Q1 2024 was $40.9 million, or $0.54 per share, compared to a $11.7 million loss in Q1 2023. Cash and cash equivalents increased to $157.9 million, thanks to significant capital raised through private placements and financing agreements.

Liquidia (NASDAQ: LQDA) will present data on the investigational use of L606 (liposomal treprostinil) inhalation suspension at the ATS 2024 International Conference. The company aims to demonstrate the safety and tolerability of L606 in patients with PAH and PH-ILD through a Phase 3, 2-part, open-label, multicenter study. The presentation will be on May 22, 2024, in San Diego, California. Liquidia plans to initiate a global pivotal efficacy trial later this year based on the study's positive results.

Liquidia (NASDAQ: LQDA) will be presenting at the BofA Securities Health Care Conference 2024, where Michael Kaseta, the COO and CFO, will update investors on the company's business. The presentation will take place on May 14, 2024, at 5:00 p.m. PT in Las Vegas, Nevada. A webcast of the event will be accessible on Liquidia's website, with a recorded version available for 30 days post-event.

Liquidia (NASDAQ: LQDA) will report its first quarter 2024 financial results on May 14, 2024. A live webcast will be hosted at 8:30 a.m. Eastern Time to discuss financial results and provide a corporate update. The webcast will be available on Liquidia's website. A rebroadcast will be archived for one year.